3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
2
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Adenocarcinoma
1
Interventions
Carboplatin
330
Pemetrexed
266
Cisplatin
234
Docetaxel
195
Paclitaxel
182
Radiotherapy
181
Erlotinib Hydrochloride
153
pembrolizumab
147
Gemcitabine
147
Bevacizumab
125
Drug Therapy
121
Radiosurgery
115
Nivolumab
112
osimertinib
92
durvalumab
88
Gefitinib
67
atezolizumab
63
Vinorelbine
63
Surgical Procedures, Operative
62
Magnetic Resonance Spectroscopy
54
anlotinib
42
Immunotherapy
42
Taxes
39
Blood Specimen Collection
39
Ipilimumab
38
130-nm albumin-bound paclitaxel
38
Specimen Handling
36
Immune Checkpoint Inhibitors
35
Radiation
34
Albumin-Bound Paclitaxel
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Non-Small-Cell Lung
×
ipatasertib
×
Clear all
NCT04467801
2023-11-07
Ipat-Lung
University of Kansas Medical Center
Phase 2
Unknown
60 enrolled
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled